Immune-Mediated Inflammatory Diseases Treatment Market
Global Immune-Mediated Inflammatory Diseases Treatment Market Size, Share & Trends Analysis Report By Disease Type (Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease, Psoriasis, Rheumatoid Arthritis, and Others), By Drug Class (Anti-Inflammatory Biologics, Non- Steroidal Anti- Inflammatory Drugs, Corticosteroids, and Others), By Treatment Type (Targeted Biologic Therapies and Novel Therapies) forecast period (2019-2025) Update Available - Forecast 2024-2030
The global immune-mediated inflammatory disease treatment market is anticipated to grow at a CAGR of over 6% during the forecast period. Immune-mediated inflammatory disease treatment has been improved significantly over the past years due to the development of a series of targeted biological therapies and novel therapies in the market. Currently, quite a lot of research is going on in the field regarding the treatment of immune-mediated disease. In addition, new drugs and treatment options are entering the market, which is fuelling the growth of the global immune-mediated inflammatory disease treatment market. For instance, in August 2019, the US FDA approved upadacitinib (Rinvoq), an oral medication for adults with moderate to severe rheumatoid arthritis that is not being well-controlled by methotrexate.
However, the late diagnosis of immune-mediated inflammatory disease coupled with challenges during the treatment such as slow or incomplete healing is limiting the growth of the global immune-mediated inflammatory disease treatment market. In addition, the high cost associated with the treatment also restricts the global immune-mediated inflammatory disease treatment market growth. For instance, due to their high costs, considerable differences in the utilization of treatment options exist across the globe. Various European countries are restricting access despite professional society guideline recommendations. Additionally, the adoption of biologic therapies for the treatment by healthcare providers has been particularly poor in many Central and Eastern European countries which are affecting the growth of immune-mediated inflammatory diseases. Moreover, the presence of a small patient base for rare disease coupled with disproportion in the availability of treatments and resources to manage patients, and train experts in developing economies will also limit the growth of the global immune-mediated inflammatory diseases treatment market.
Segmental Outlook
The global immune-mediated inflammatory disease treatment market is segmented on the basis of disease type, drug class, and treatment type. Based on disease type, the market is sub-segmented into multiple sclerosis, psoriasis, inflammatory bowel disease, psoriasis, rheumatoid arthritis, and others. Based on the drug class, the market is segmented into anti-inflammatory biologics, non- steroidal anti-inflammatory drugs, corticosteroids, and others. Based on treatment type, the market is bifurcated into targeted biologic therapies and novel therapies.
Global Immune-Mediated Inflammatory Diseases Treatment Market Share by Treatment Type, 2018 (%)
Treatment Type Insights: Targeted Biologic Therapies to Hold a Significant Share
Targeted biologic therapies segment is anticipated to hold a significant share in the global immune-mediated inflammatory disease treatment market owing to the increasing adoption of therapy coupled with the increasing number of rheumatoid arthritis cases and other immune-mediated inflammatory diseases across the globe.
Targeted biologic therapy is an effective treatment for a range of immune-mediated inflammatory diseases including rheumatoid arthritis, psoriasis, and inflammatory bowel diseases. According to the National Institute of Health, the approach of targeting cytokines has dramatically improved the success in the treatment of rheumatoid arthritis. In addition, targeted therapies are less expensive alternatives to many already licensed biological therapies and provide more quality, safety, and efficacy, which in turn, is driving the segmental growth of the market.
Regional Outlooks
The global immune-mediated inflammatory disease treatment market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. North America is estimated to hold a prominent share in the global immune-mediated inflammatory disease treatment market owing to the presence of major pharmaceutical market players in the region coupled with the increasing healthcare expenditure.
Global Immune-Mediated Inflammatory Diseases Treatment Market Growth by Region, 2019-2025
Market Players Outlook
Some of the key players operating in the global immune-mediated inflammatory diseases treatment market include Abbvie Inc., AstraZeneca PLC, Bristol Myers Squibb Co., Pfizer Inc., Amgen Inc., GlaxoSmithKline PLC, Eli Lilly and Co., F. Hoffmann-La Roche AG, Daiichi Sankyo Co. Ltd., Gilead Sciences, Inc., Novartis International AG, and others. The market players are considerably contributing to the market growth by adopting various strategies including new product launch, mergers and acquisitions, collaborations with government, and others to stay competitive in the market.
Recent Activity
- In March 2020, Roche has initiated a late-stage trial assessing its rheumatoid arthritis drug Actemra in patients who have severe COVID-19 caused pneumonia. The company launched a Phase III Study of Rheumatoid Arthritis drug for COVID-19 pneumonia.
- In May 2018, Daiichi Sankyo announced the development of their new drug to treat intractable immune-mediated inflammatory diseases, as, from existing standards, it is difficult to cure cases of intractable and rare diseases. Hence this development will help to cure such diseases. With this development, the company aims to provide better treatment options to the patients.
The Report Covers
- Market value data analysis of 2018 and forecast to 2025.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global immune-mediated inflammatory disease treatment market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. AstraZeneca PLC
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Amgen Inc.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. AbbVie Inc.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. GlaxoSmithKline PLC
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Bristol-Myers Squibb Co.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.1. Opportunities
5. Market Segmentation
5.1. Global Immune-Mediated Inflammatory Diseases Treatment Market by Disease Type
5.1.1. Multiple Sclerosis
5.1.2. Psoriasis
5.1.3. Inflammatory Bowel Disease
5.1.4. Rheumatoid Arthritis
5.1.5. Others
5.2. Global immune-Mediated inflammatory diseases treatment Market by Drug Class
5.2.1. Anti- Inflammatory Biologics
5.2.2. Non- Steroidal Anti- Inflammatory Drugs
5.2.3. Corticosteroids
5.3. Global immune-Mediated inflammatory diseases treatment Market by Treatment Type
5.3.1. Targeted Biologic Therapies
5.3.2. Novel Therapies
6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Abbvie Inc.
7.2. Abivax SA
7.3. AstraZeneca PLC
7.4. Boehringer Ingelheim International GmbH
7.5. Bristol-Myers Squibb Co.
7.6. Celgene Corp.
7.7. Daiichi Sankyo Co., Ltd.
7.8. Eli Lilly and Co.
7.9. F. Hoffmann-La Roche Ltd.
7.10. Gilead Sciences, Inc.
7.11. GlaxoSmithKline PLC
7.12. Innovate Biopharmaceuticals Inc.
7.13. Johnson & Johnson Services Inc.
7.14. LG Chem Ltd.
7.15. Merck & Co., Inc.
7.16. Merck KGaA
7.17. Novartis International AG
7.18. Pharmaxis Ltd.
7.19. Sanofi S.A.
7.20. UCB S.A.
7.21. Ventria Bioscience Inc.
1. GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
2. GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
3. GLOBAL MARKET PSORIASIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
4. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
5. GLOBAL RHEUMATOID ARTHRITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
6. GLOBAL OTHER IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
7. GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
8. GLOBAL ANTI-INFLAMMATORY BIOLOGICS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
9. GLOBAL NON- STERIODAL ANTI- INFLAMMATORY DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
10. GLOBAL CORTICOSTERIOIDS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
11. GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
12. GLOBAL TARGETED BIOLOGIC THERAPIES FOR IMMUNE-MEDIATED INFLAMMATORY DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
13. GLOBAL NOVEL THERAPIES FOR IMMUNE-MEDIATED INFLAMMATORY DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
14. GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
15. NORTH AMERICAN IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
16. NORTH AMERICAN IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
17. NORTH AMERICAN IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
18. NORTH AMERICAN IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
19. EUROPEAN IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
20. EUROPEAN IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
21. EUROPEAN IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
22. EUROPEAN IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
23. ASIA-PACIFIC IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
24. ASIA-PACIFIC IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
25. ASIA-PACIFIC IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
26. ASIA-PACIFIC IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
27. REST OF THE WORLD IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
28. REST OF THE WORLD IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
29. REST OF THE WORLD IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
1. GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET SHARE BY DISEASE TYPE, 2018 VS 2025 (%)
2. GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET SHARE BY DRUG CLASS, 2018 VS 2025 (%)
3. GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET SHARE BY TREATMENT TYPE, 2018 VS 2025 (%)
4. GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
5. US IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
6. CANADA IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
7. UK IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
8. FRANCE IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
9. GERMANY IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
10. ITALY IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
11. SPAIN IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
12. ROE IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
13. INDIA IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
14. CHINA IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
15. JAPAN IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
16. REST OF ASIA-PACIFIC IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
17. REST OF THE WORLD IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
